重症肌无力与安全用药  

Myasthenia Gravis and Safe Drug Use

作　　者：Morgan Marriott Abbey Schwery Amy VandenBerg 谭颖 朱珠[3] 管宇宙 Morgan Marriott;Abbey Schwery;Amy VandenBerg;TAN Ying;ZHU Zhu;GUAN Yu-zhou(不详;Department of Neurology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China;Department of Pharmacy,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100730,China)

机构地区：[1]不详 [2]中国医学科学院北京协和医学院-北京协和医院神经科 [3]中国医学科学院北京协和医学院-北京协和医院药剂科

出　　处：《中国合理用药探索》2022年第12期1-9,共9页Chinese Journal of Rational Drug Use

摘　　要：重症肌无力(MG)是一种自身免疫性疾病,患者体内会产生针对神经肌肉接头(NMJ)的自身抗体,从而导致骨骼肌收缩受损。MG的主要治疗药物是免疫抑制剂和乙酰胆碱酯酶抑制剂,但关于哪种药物最有效的证据有限。本文旨在协助临床医生对MG病理生理学和治疗原则进行一定程度的理解,并描述可能导致MG发病或急性恶化的常用药物。Myasthenia gravis(MG)is an autoimmune disorder in which patients develop autoantibodies to a component of the neuromuscular junction(NMJ),resulting in impairment of skeletal muscle contraction.Immunosuppressant medications and acetylcholinesterase inhibitors are the mainstays of treatment,although there is limited evidence as to which agents are most effi cacious.The purpose of this therapeutic update is to provide clinician with a general understanding of the pathophysiology and treatment of MG and describe common medications with the potential to cause new onset or acute worsening of this disease.

关 键 词：乙酰胆碱 抗菌药物 急性加重 重症肌无力 神经肌肉接头 

分 类 号：R746.1[医药卫生—神经病学与精神病学]